- €29.70m
- €30.33m
- €22.06m
- 81
- 53
- 42
- 62
Annual income statement for genOway SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | — | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11 | 14 | 17.1 | 20 | 22.1 |
| Cost of Revenue | |||||
| Gross Profit | 11 | 12.8 | 16.2 | 19.2 | 20.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11.5 | 14.1 | 15.7 | 18 | 19.9 |
| Operating Profit | -0.533 | -0.069 | 1.4 | 2.07 | 2.12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.611 | -0.092 | 1.08 | 1.96 | 2.26 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.687 | -0.323 | 0.778 | 1.57 | 1.83 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.687 | -0.323 | 0.778 | 1.57 | 1.83 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.687 | -0.323 | 0.778 | 1.57 | 1.83 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.083 | -0.064 | 0.052 | 0.178 | 0.182 |
| Dividends per Share |